RNA interference therapeutic

This page covers all RNA interference therapeutic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PHXC mRNA.

Targets

PHXC mRNA

Phase 3 pipeline (1)

• DCR-PHXC · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Genetic/Metabolic Disease
  DCR-PHXC is an RNA interference therapeutic that silences the PHXC gene to reduce production of a disease-causing protein.

Patent intelligence

• rna interference therapeutic patent landscape — aggregated cliff calendar, attackable patents, originator estates